Other3

Retension Pharmaceuticals, Inc.

Total Value

$NaN

Filing Date

Oct 16, 2026

1 transactions

Trade Summary

On Oct 13, 2026, B Group, Inc., 10% Owner, reported $NaN of Retension Pharmaceuticals, Inc. (RTSN) across 1 transactions. The filing covers company securities and reflects balanced net activity of $NaN. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: B Group, Inc.
Role: 10% Owner
Location: DALLAS, TX

Filing Details

Filing Date: Oct 16, 2026
Transaction Date: Oct 13, 2026
Accession Number: 0001213900-26-110379
Form Type: 3

Want live alerts when B Group, Inc. trades again?

Download Insider Trades to track RTSN, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)The reporting persons are The B Group, Inc. ("B Group"), B Group Capital LLC (the "Fund") and Branden B. Muhl. B Group is the investment adviser of the Fund. Mr. Muhl is the manager and controlling owner of the Fund and B Group, respectively. B Group is filing this Form 3 for itself, the Fund and Mr. Muhl. The securities are held directly by the Fund. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 3d-5(b) under the Securities Exchange Act of 1934, as amended. B Group may be deemed to indirectly beneficially own the securities as the investment adviser to the Fund. Mr. Muhl may be deemed to indirectly beneficially own securities as the manager of the Fund and control person of B Group. The reporting persons disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

B Group, Inc.

(Last)

(First)

(Middle)

2900 MCKINNON STREET

SUITE 1101

(Street)

DALLAS

75201

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/13/2026

3. Issuer Name and Ticker or Trading Symbol
Retension Pharmaceuticals, Inc. [ RTSN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	833,333	I	See Note 1⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

1. The reporting persons are The B Group, Inc. ("B Group"), B Group Capital LLC (the "Fund") and Branden B. Muhl. B Group is the investment adviser of the Fund. Mr. Muhl is the manager and controlling owner of the Fund and B Group, respectively. B Group is filing this Form 3 for itself, the Fund and Mr. Muhl. The securities are held directly by the Fund. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 3d-5(b) under the Securities Exchange Act of 1934, as amended. B Group may be deemed to indirectly beneficially own the securities as the investment adviser to the Fund. Mr. Muhl may be deemed to indirectly beneficially own securities as the manager of the Fund and control person of B Group. The reporting persons disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.

	/s/ Branden B. Muhl, Chief Executive Officer	10/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 3 as rendered by the SEC from accession 0001213900-26-110379.

Retension Pharmaceuticals, Inc.

Trade Summary

Company Information

Insider Information

Filing Details

Want live alerts when B Group, Inc. trades again?

Footnotes

SEC Form 3

SEC Filing

SEC Form 3